CHGN 111Alternative Names: CHGN111
Latest Information Update: 18 Sep 2015
At a glance
- Originator Chronogen
- Mechanism of Action CDC-like kinase-1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Photodamage
Most Recent Events
- 18 Sep 2015 Discontinued - Preclinical for Photodamage in Canada (Topical)
- 01 May 2006 Preclinical trials in Photodamage prevention in Canada (Topical)